Literature DB >> 2510121

Mixed bacterial and viral infections are common in children.

J Hietala1, M Uhari, H Tuokko, M Leinonen.   

Abstract

Acute phase and convalescent sera from 51 pediatric patients who had a documented viral infection and no obvious culture-confirmed bacterial infection such as meningitis, otitis media or urinary tract infection were tested by enzyme immunoassay for antibodies to Haemophilus influenzae and Branhamella catarrhalis and by the latex agglutination test for pneumococcal antigens to evaluate the frequency of mixed bacterial and viral infections. A mixed bacterial and viral infection was documented in 19 patients (37%). Seven patients (14%) showed a diagnostic rise in antibodies to H. influenzae and 8 patients (16%) showed an antibody elevation to B. catarrhalis in their paired sera; pneumococcal antigen was detected in acute phase serum from 4 patients (8%). The rate of mixed infections in patients having respiratory symptoms was 52%. High serum C-reactive protein values and white blood cell counts were found significantly more often in those with mixed infections than in those who had viral infections. The results indicate that mixed bacterial and viral infections occur more frequently in children than one could anticipate on the basis of the earlier reports. Mixed bacterial and viral etiology is highly probable in a child who has a defined viral infection with high C-reactive protein and white blood cell count values, especially in the presence of respiratory symptoms.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2510121     DOI: 10.1097/00006454-198910000-00004

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  10 in total

1.  Rationalised prescribing for community acquired pneumonia: a closed loop audit.

Authors:  H Clements; T Stephenson; V Gabriel; T Harrison; M Millar; A Smyth; W Tong; C J Linton
Journal:  Arch Dis Child       Date:  2000-10       Impact factor: 3.791

2.  Fimbria-mediated enhanced attachment of nontypeable Haemophilus influenzae to respiratory syncytial virus-infected respiratory epithelial cells.

Authors:  Z Jiang; N Nagata; E Molina; L O Bakaletz; H Hawkins; J A Patel
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

3.  Pneumonia in childhood: etiology and response to antimicrobial therapy.

Authors:  O Ruuskanen; H Nohynek; T Ziegler; R Capeding; H Rikalainen; P Huovinen; M Leinonen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-03       Impact factor: 3.267

Review 4.  Classification and treatment of pneumonia.

Authors:  R Bahl; N Bhandari; M K Bhan
Journal:  Indian J Pediatr       Date:  1994 Nov-Dec       Impact factor: 1.967

Review 5.  Short-course therapy for community-acquired pneumonia in paediatric patients.

Authors:  Shamim Qazi
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Non-typeable Haemophilus influenzae protects human airway epithelial cells from a subsequent respiratory syncytial virus challenge.

Authors:  Stacey M Hartwig; Margaret Ketterer; Michael A Apicella; Steven M Varga
Journal:  Virology       Date:  2016-08-27       Impact factor: 3.616

7.  Effect of respiratory syncytial virus infection on binding of Neisseria meningitidis and Haemophilus influenzae type b to a human epithelial cell line (HEp-2).

Authors:  M W Raza; M M Ogilvie; C C Blackwell; J Stewart; R A Elton; D M Weir
Journal:  Epidemiol Infect       Date:  1993-04       Impact factor: 2.451

8.  Treatment of acute bronchiolitis with Chinese herbs.

Authors:  X T Kong; H T Fang; G Q Jiang; S Z Zhai; D L O'Connell; D R Brewster
Journal:  Arch Dis Child       Date:  1993-04       Impact factor: 3.791

Review 9.  Respiratory syncytial virus.

Authors:  O Ruuskanen; P L Ogra
Journal:  Curr Probl Pediatr       Date:  1993-02

10.  Aetiology of community-acquired pneumonia in children treated in hospital.

Authors:  M Korppi; T Heiskanen-Kosma; E Jalonen; P Saikku; M Leinonen; P Halonen; P H Mäkela
Journal:  Eur J Pediatr       Date:  1993-01       Impact factor: 3.183

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.